Get the Stockscreener App
0.7313
3.00%
0.0213
After Hours:
.62
-0.1113
-15.22%
Scynexis Inc stock is traded at $0.7313, with a volume of 368.28K.
It is up +3.00% in the last 24 hours and down -29.00% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.71
Open:
$0.7
24h Volume:
368.28K
Relative Volume:
0.67
Market Cap:
$58.10M
Revenue:
$20.60M
Net Income/Loss:
$-8.61M
P/E Ratio:
-5.2954
EPS:
-0.1381
Net Cash Flow:
$-5.28M
1W Performance:
-1.18%
1M Performance:
-29.00%
6M Performance:
+7.54%
1Y Performance:
-5.01%
1-Day Range:
$0.67
$0.7355
1-Week Range:
$0.6328
$0.7367
52-Week Range:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.7313 | 56.40M | 20.60M | -8.61M | -5.28M | -0.1381 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
SCYNEXIS to implement 1-for-8 reverse stock split - MSN
SCYNEXIS (SCYX) Announces 1-for-8 Reverse Stock Split to Meet Na - GuruFocus
SCYNEXIS announces 1-for-8 reverse stock split effective May 29 - Investing.com UK
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split - TipRanks
SCYNEXIS announces 1-for-8 reverse stock split effective May 29 By Investing.com - Investing.com South Africa
Scynexis stock falls 7% on reverse stock split announcement - Investing.com
SCYNEXIS Announces One-for-Eight Reverse Stock Split - The Manila Times
Biotech SCYNEXIS shrinks share count with 1-for-8 reverse split - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYX: Shareholders approved a reverse stock split and reduction of authorized shares - TradingView
SCYX: Reverse stock split and share reduction approved; no questions or other proposals raised - TradingView
SCYNEXIS (SCYX) approves 1-for-8 reverse stock split and major cut to authorized shares - Stock Titan
SCYNEXIS (SCYX) Falls -7.43% — Watching $0.66 Support 2026-05-18Overbought Alert - Newser
Why did SCYX stock jump 10% in pre-market today? - MSN
Press Releases about SCYNEXIS, Inc.Common Stock - The Chronicle-Journal
CVI Investments and Heights disclose 6.2% stake in SCYNEXIS (SCYX) - Stock Titan
SCYNEXIS (SCYX) price target increased by 20.73% to 4.28 - MSN
SCYNEXIS (SCYX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Financial Overview of SCYX: Cash Position Strengthened - GuruFocus
Scynexis: Q1 Earnings Snapshot - marketscreener.com
Rare-disease biotech SCYNEXIS buys kidney-drug candidate, funds runway to 2029 - Stock Titan
BRIEF-Scynexis Q1 Operating Expenses USD 16.939 Million - TradingView
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
SCYNEXIS (SCYX) boosts cash with $40M raise as R&D spend jumps in Q1 2026 - Stock Titan
[EFFECT] SCYNEXIS INC SEC Filing - Stock Titan
Press Release: SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Scynexis | SCHEDULE 13G: Others - Moomoo
MSN Money - MSN
SCYNEXIS (NASDAQ: SCYX) registers 87M shares for resale by private‑placement buyers - Stock Titan
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SCYNEXIS Grants Options for 259,500 Shares to New Employees - geneonline.com
Scynexis Deadline Reminder - TMX Newsfile
New SCYNEXIS vice president gets options for 125,000 shares - Stock Titan
SCYX Forecast, Price Target & Analyst Ratings | SCYNEXIS INC (NASDAQ:SCYX) - ChartMill
SCYX (SCYNEXIS) posts 87.3 percent Q4 2025 EPS beat, while shares dip slightly in today’s trading. - Newser
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):